{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:01:28Z","timestamp":1772006488584,"version":"3.50.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The absence of an immediately deployable, broad-spectrum antiviral remains a critical vulnerability in global pandemic preparedness. Host-directed agents that activate innate immunity offer a pathogen-agnostic strategy, yet no such therapy is currently stockpiled or authorized for emergency use. Infectious Bursal Disease Virus (IBDV)\u2014a non-replicating avian dsRNA vaccine virus with a 60-year safety record in poultry\u2014induces robust interferon responses in mammals and has been administered orally in marmosets and more than 50 human patients with hepatitis A, B, C, SARS-CoV-2, and herpes zoster infections. These observations include a randomized phase II trial in 84 acute HBV\/HCV patients. Although the evidence base is limited, the consistency of clinical responses and absence of serious safety signals justify renewed scientific examination. This review synthesizes the mechanistic rationale, comparative advantages over synthetic Pattern Recognition Receptor (PRR) agonists, clinical observations, One Health implications, and regulatory precedents relevant to evaluating IBDV as a temporary, compassionate-use antiviral during pandemics while the reverse-engineered human candidate (IBDV-R903\/78) progresses through formal development. The goal is not to endorse clinical deployment, but to initiate a rigorous, multidisciplinary debate on whether an established veterinary dsRNA vaccine virus could serve as an off-the-shelf host-directed live viral adjuvant therapy in future public health emergencies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1760109","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:05:15Z","timestamp":1772003115000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Host-targeted oral avian vaccine virus demonstrates broad antiviral activity and safety in patients"],"prefix":"10.3389","volume":"17","author":[{"given":"Tibor","family":"Bakacs","sequence":"first","affiliation":[{"name":"Hungarian Research Network (HUN-REN) Alfr\u00e9d R\u00e9nyi Mathematical Research Institute","place":["Budapest, Hungary"]},{"name":"HepC Therapeutics Inc.","place":["Budapest, Hungary"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Chumakov","sequence":"additional","affiliation":[{"name":"George Washington University","place":["Washington DC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01439-9","article-title":"Global health 2050: the path to halving premature death by mid-century","volume":"404","author":"Jamison","year":"2024","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/14888386.2006.9712792","article-title":"The diversity of viruses infecting humans","volume":"7","author":"Mahy","year":"2006","journal-title":"Biodiversity (Nepean)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"Clercq","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/pathogens14010020","article-title":"Advances and challenges in antiviral development for respiratory viruses","volume":"14","author":"De Jes\u00fas-Gonz\u00e1lez","year":"2025","journal-title":"Pathogens"},{"key":"B5","first-page":"19","article-title":"Animal markets and zoonotic disease risk: A global synthesis of a 15 country study","volume":"163","author":"Ann Linder MS","year":"2024","journal-title":"Harvard Law School"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1046851","article-title":"Editorial: Fighting fire with fire: Using non-pathogenic viruses to control unrelated infections","volume":"13","author":"Bakacs","year":"2022","journal-title":"Front Immunol"},{"key":"B7","first-page":"191","article-title":"Potential use of nonpathogenic enteroviruses for control of human disease","volume":"36","author":"Voroshilova","year":"1989","journal-title":"Prog Med Virol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.04.042","article-title":"Trained immunity: a tool for reducing susceptibility to and the severity of SARS-coV-2 infection","volume":"181","author":"Netea","year":"2020","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e2101718118","DOI":"10.1073\/pnas.2101718118","article-title":"Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics","volume":"118","author":"Chumakov","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.907341","article-title":"Vaccination with oral polio vaccine reduces COVID-19 incidence","volume":"13","author":"Yagovkina","year":"2022","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.32388\/AZ4JZV","article-title":"A harmless avian vaccine virus could be developed into an off-the-shelf \u201cAntibiotic\u201d for viruses","volume":"15","author":"Bakacs","year":"2024","journal-title":"Qeios"},{"key":"B12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1096\/fj.201800062RR","article-title":"STAU1 binds to IBDV genomic double-stranded RNA and promotes viral replication via attenuation of MDA5-dependent \u03b2 interferon induction","volume":"33","author":"Ye","year":"2019","journal-title":"FASEB J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859749","article-title":"Discovery and use of long dsRNA mediated RNA interference to stimulate antiviral protection in interferon competent mammalian cells","volume":"13","author":"Semple","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201695086","article-title":"Inactivation of the type I interferon pathway reveals long double-stranded RNA-mediated RNA interference in mammalian cells","volume":"35","author":"Maillard","year":"2016","journal-title":"EMBO J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.32388\/S7SMJS","article-title":"Sting pathway activation by orally administered attenuated dsRNA vaccine virus for therapy of viral diseases","author":"Bakacs","year":"2024","journal-title":"Qeios"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.09.027","article-title":"Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression","volume":"78","author":"Gane","year":"2023","journal-title":"J Hepatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1473-3099(22)00727-7","article-title":"TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial","volume":"23","author":"Yuen","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2024.1428713","article-title":"Safety and efficacy of toll-like receptor agonists as therapeutic agents and vaccine adjuvants for infectious diseases in animals: a systematic review","volume":"11","author":"Oboge","year":"2024","journal-title":"Front Vet Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(23)00095-8","article-title":"Advances in viral hepatitis B and D: moving toward the goals of elimination","volume":"27","author":"Gish","year":"2023","journal-title":"Clin Liver Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2023.1168649","article-title":"Livestock health and disease economics: a scoping review of selected literature","volume":"10","author":"Kappes","year":"2023","journal-title":". Front Veterinary Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.37421\/2952-8097.2024.8.241","article-title":"The economic impact of emergency animal diseases: assessing costs and mitigation strategies","volume":"8","author":"Rosso","year":"2024","journal-title":"J Anim Health Behav Sci"},{"key":"B22","article-title":"Interference between human hepatitis A virus and an attenuated apathogenic avian virus","volume":"31","author":"Csatary","year":"1984","journal-title":"Acta Microbiol Hung"},{"key":"B23","article-title":"Preliminary report of a controlled trial of MTH-68\/B virus vaccine treatment in acute B and C hepatitis: a phase II study","volume":"18","author":"Csatary","year":"1998","journal-title":"Anticancer Res"},{"key":"B24","article-title":"Successful treatment of decompensated chronic viral hepatitis by bursal disease virus vaccine","volume":"19","author":"Csatary","year":"1999","journal-title":"Anticancer Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e28467","DOI":"10.7759\/cureus.28467","article-title":"An orally administered nonpathogenic attenuated vaccine virus can be used to control SARSCoV-2 infection: A complementary plan B to COVID-19 vaccination","volume":"14","author":"Bakacs","year":"2022","journal-title":"Cureus"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e20303","DOI":"10.7759\/cureus.20303","article-title":"Healing of severe herpes zoster ophthalmicus within a few days: an autobiographical case report","volume":"13","author":"Bakacs","year":"2021","journal-title":"Cureus"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.vaccine.2004.08.005","article-title":"Examination of the value of treatment of decompensated viral hepatitis patients by intentionally coinfecting them with an apathogenic IBDV and using the lessons learnt to seriously consider treating patients infected with HIV using the apathogenic hepatitis G virus","volume":"23","author":"Bakacs","year":"2004","journal-title":"Vaccine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.2830","article-title":"Effective multiple oral administration of reverse genetics engineered infectious bursal disease virus in mice in the presence of neutralizing antibodies","volume":"17","author":"Hornyak","year":"2015","journal-title":"Gene Med"},{"key":"B29","first-page":"S","article-title":"Intentional superinfection of decompensated chronic viral hepatitis by avian infectious bursal disease virus shows promise","volume":"26","author":"Bak\u00e1cs","year":"2002","journal-title":"Cancer Detect Prev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41124-017-0028-x","article-title":"Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needs","volume":"3","author":"Bakacs","year":"2018","journal-title":"Hepatol Med Policy"},{"key":"B31","article-title":"Herpes zoster ophthalmicus","volume-title":"StatPearls","author":"Minor","year":"2025"},{"key":"B32","doi-asserted-by":"publisher","first-page":"100336","DOI":"10.1016\/j.ebr.2019.100336","article-title":"Making the switch: From case studies to N-of-1 trials","volume":"12","author":"Margolis","year":"2019","journal-title":"Epilepsy Behav Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/ph16020226","article-title":"Combination therapy for the treatment of shingles with an immunostimulatory vaccine virus and acyclovir","volume":"16","author":"Bakacs","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41559-024-02353-4","article-title":"The evolutionary drivers and correlates of viral host jumps","volume":"8","author":"Tan","year":"2024","journal-title":"Nat Ecol Evol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/ve\/vex007","article-title":"Adaptation of avian influenza virus to a swine host","volume":"3","author":"Bourret","year":"2017","journal-title":"Virus Evol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e1008330","DOI":"10.1371\/journal.ppat.1008330","article-title":"A unique feature of swine ANP32A provides susceptibility to avian influenza virus infection in pigs","volume":"16","author":"Zhang","year":"2020","journal-title":"PloS Pathog"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2174\/1871526522666220419130403","article-title":"A clinically validated, broadly active, oral viral superinfection therapy could mitigate symptoms in early-stage COVID-19 patients","volume":"22","author":"Bakacs","year":"2022","journal-title":"Infect Disord Drug Targets"},{"key":"B38","first-page":"199","article-title":"Pandemics and Health Security: Risks to Global Stability","volume-title":"Global Security in an Age of Crisis","author":"Sorrell","year":"2023"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01489-8","article-title":"Unifying forces to strengthen pandemic preparedness: a call for a Global Pandemic Risk Observatory","volume":"406","author":"Dzau","year":"2025","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-91021-1_8","article-title":"The Economics of Pandemics as a Globally Shared Experience: A Theory","volume-title":"The Economics of Pandemics: Exploring Globally Shared Experiences","author":"Seo","year":"2022"},{"key":"B41","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13017-025-00656-w","article-title":"Global health at crossroads: uniting together to overcome challenges, restore trust and advance priorities for a sustainable future","volume":"20","author":"Sartelli","year":"2025","journal-title":"World J Emerg Surg"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/science.adt0180","article-title":"A single mutation in bovine influenza H5N1 hemagglutinin switches specificity to human receptors","volume":"386","author":"Lin","year":"2024","journal-title":"Science"},{"key":"B43","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/d41586-022-04423-8","article-title":"Even after COVID, the world\u2019s vaccine strategy is failing","volume":"612","author":"Berkley","year":"2022","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2022.978901","article-title":"Efficacy of live attenuated, vector and immune complex infectious bursal disease virus (IBDV) vaccines in preventing field strain bursa colonization: A European multicentric study","volume":"9","author":"Ramon","year":"2022","journal-title":"Front Veterinary Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2183\/pjab.87.13","article-title":"Ivermectin, \u2018Wonder drug\u2019 from Japan: the human use perspective","volume":"87","author":"Crump","year":"2011","journal-title":"Proc Japan Academy Ser B"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/science.118.3062.259","article-title":"Streptomycin: background, isolation, properties, and utilization","author":"Waksman","year":"1953","journal-title":"Science"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e22750","DOI":"10.7759\/cureus.22750","article-title":"Sequential combination of a strong interferon inducer viral vector with low doses of nivolumab plus ipilimumab could provide functional cure in chronic hepatitis B virus infections: technical report proposing a new modality","volume":"14","author":"Bakacs","year":"2022","journal-title":"Cureus"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1760109\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:05:17Z","timestamp":1772003117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1760109\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2026.1760109"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1760109","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"article-number":"1760109"}}